Research and Markets (http://www.researchandmarkets.com/research/658cql/lemtrada)
has announced the addition of the "2014
Report on the International Lemtrada - Forecast and Market Analysis to
2022" report to their offering.
Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder
characterized pathologically by demyelination, axonal transection and
neurodegeneration within the central nervous system. With curative
therapy still elusive, current disease management is dependent on
life-long pharmacotherapy with disease-modifying therapies (DMT).
The dominance of first-line injectable DMTs, including the interferon
beta (IFNß) agents: Bayer's Betaseron/Betaferon (IFNß-1b), Biogen's
Avonex (IFNß-1a) andMerck's Rebif (IFNß-1a), and Teva's Copaxone
(glatiramer acetate), has been a salient feature of the MS therapeutics
market. However, the competitive landscape is undergoing significant
change with the emergence of oral therapies, several pipeline products
with notable efficacies, and looming generics/biosimilars following the
patent expiries of key branded products during the forecast period. In
addition, the entry of new companies such as Sanofi/Genzyme and F.
Hoffmann-La-Roche/Genentech will challenge the position of the
established players in the MS marketplace.
Lemtrada (alemtuzumab) is an IV-administered humanized mAb being
investigated as a potential therapy for RRMS. Sanofi's and Genzyme's
Lemtrada is currently being developed in collaboration with Bayer
HealthCare, which has recently announced its intention to co-promote the
drug for MS. It is approved under the trade name Campath as a
monotherapy for the treatment of B-cell chronic lymphocytic leukemia
(CLL). However, Sanofi's Genzyme unit recently decided to withdraw
Campath from the US and EU markets in order to optimize the drug as a
treatment for MS. By using a different dose and the trade name Lemtrada,
the company is making a bid to stop physicians from prescribing the drug
off-label for MS.
Key Topics Covered:
1 List of Tables and Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Lemtrada (alemtuzumab)
For more information visit http://www.researchandmarkets.com/research/658cql/lemtrada
[ Back To NFVZone's Homepage ]